Autoimmune lymphoproliferative syndrome: An update and review of the literature

Current Allergy and Asthma Reports

Volumn 14, Issue 9, 2014, Pages

  Shah, Shaili ^a   Wu, Eveline ^a   Rao, V Koneti ^b   Tarrant, Teresa K ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apoptosis; Autoimmune lymphoproliferative syndrome (ALPS); Autoimmunity; Primary immunodeficiency; Review

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 17; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RAPAMYCIN; RITUXIMAB; ANTIINFLAMMATORY AGENT; FAS ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GENETIC DISORDER; HUMAN; IMMUNOTHERAPY; INCIDENCE; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; APOPTOSIS; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPLENOMEGALY; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; SPLENOMEGALY; T-LYMPHOCYTES;

EID: 84905287000     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-014-0462-4     Document Type: Review

References (33)

1. Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood. 2011;118(22):5741-51. Discusses management of various complications related to ALPS based on study of a large cohort of ALPS patients.
2. Fisher GH et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935-46.
3. Straus SE et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98(1):194-200.
4. Hauck F et al. Somatic loss of heterozygosity, but not haploinsufficiency alone, leads to full-blown autoimmune lymphoproliferative syndrome in 1 of 12 family members with FAS start codon mutation. Clin Immunol. 2013;147(1):61-8.
5. Del-Rey M et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood. 2006;108(4):1306-12. (Pubitemid 44232029)
6. Zhu S et al. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome. Hum Genet. 2006;119(3):284-94.
7. Wang J et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98(1):47-58. (Pubitemid 29331195)
8. Lambotte O et al. Diagnosis of autoimmune lymphoproliferative syndrome caused by FAS deficiency in adults. Haematologica. 2013;98(3):389-92.
9. Deutsch M, Tsopanou E, Dourakis SP. The autoimmune lymphoproliferative syndrome (Canale-Smith) in adulthood. Clin Rheumatol. 2004;23(1):43-4. (Pubitemid 38247971)
10. Rudman Spergel A et al. Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis. Pediatrics. 2013;132(5):e1440-4.
11. Magerus-Chatinet A et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Investig. 2011;121(1):106-12.
12. Neven B et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118(18):4798-807.
13. Kim YJ et al. Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome. Am J Hematol. 2007;82(7):615-24.
14. Caminha I et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2010;125(4):946-9.e6.
15. Bowen RA et al. Elevated vitamin B(1)(2) levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes. Clin Biochem. 2012;45(6):490-2.
16. Oliveira JB et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14): e35-40. Discusses current diagnostic criteria for ALPS.
17. Desai NK et al. Autoimmune lymphoproliferative disorder in an adult patient. J Postgrad Med. 2011;57(2):131-3.
18. Rao VK et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009;52(7):847-52.
19. Wei A, Cowie T. Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-sitemutation (IVS7+2T>C) affecting the Fas gene. Eur J Haematol. 2007;79(4):363-6. (Pubitemid 47390134)
20. Arora S et al. Autoimmune lymphoproliferative syndrome: response to mycophenolate mofetil and pyrimethamine/sulfadoxine in a 5-year-old child. Indian J Hematol Blood Transfus. 2011;27(2):101-3.
21. Teachey DT et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145(1):101-6.
22. Teachey DTet al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006;108(6):1965-71.
23. Bajwa R, Savelli S, Gross T. Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer. 2011;57(2):336-7.
24. Kotb R et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75(1):60-4. (Pubitemid 40873963)
25. Farruggia P et al. Effectiveness of cyclosporine and mycophenolate mofetil in a child with refractory evans syndrome. Pediatr Rep. 2011;3(2):e15.
26. Liang Y et al. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One. 2012;7(5):e36698.
27. Price S et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123(13):1989-99. Discusses long term follow-up, including morbidity and mortality, of a large cohort of ALPS patients.
28. Price S, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014.
29. Boggio E, et al. IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes. Blood. 2013.
30. Benkerrou M et al. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol. 1997;27(8):2043-7. (Pubitemid 27346022)
31. Dimopoulou MN et al. Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion. Bone Marrow Transplant. 2007;40(6):605-6. (Pubitemid 47382135)
32. Sleight BJ et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant. 1998;22(4):375-80. (Pubitemid 28401078)
33. Venkataraman G et al. Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease. Am J Surg Pathol. 2010;34(4):589-94.